Cetuximab in treatment of metastatic colorectal cancer: final survival analyses and extended RAS data from the NORDIC-VII study

BACKGROUND: The NORDIC-VII study is a randomised phase III trial of cetuximab plus continuous or intermittent fluorouracil, folinic acid, and oxaliplatin (Nordic FLOX) vs FLOX alone in first-line treatment of metastatic colorectal cancer. The present report presents an updated and final survival ana...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Br J Cancer
Glavni autori: Guren, Tormod Kyrre, Thomsen, Maria, Kure, Elin H, Sorbye, Halfdan, Glimelius, Bengt, Pfeiffer, Per, Österlund, Pia, Sigurdsson, Fridbjörn, Lothe, Inger Marie Bowitz, Dalsgaard, Astrid Marie, Skovlund, Eva, Christoffersen, Thoralf, Tveit, Kjell Magne
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group 2017
Teme:
Clinical Study
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5482736/
https://ncbi.nlm.nih.gov/pubmed/28399112
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2017.93
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items